Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-02-21
DOI
10.1038/s41598-017-00075-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CELF4Variant and Anthracycline-Related Cardiomyopathy: A Children’s Oncology Group Genome-Wide Association Study
- (2016) Xuexia Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Evidence for association of SNPs inABCB1andCBR3, but notRAC2, NCF4, SLC28A3orTOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines
- (2016) Daniel L Hertz et al. PHARMACOGENOMICS
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) E. Senkus et al. ANNALS OF ONCOLOGY
- Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) H. Tilly et al. ANNALS OF ONCOLOGY
- Assessing the quality of published genetic association studies in meta-analyses: the quality of genetic studies (Q-Genie) tool
- (2015) Zahra N. Sohani et al. BMC GENETICS
- Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients
- (2015) Christof Vulsteke et al. BREAST CANCER RESEARCH AND TREATMENT
- A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer
- (2015) Folefac Aminkeng et al. NATURE GENETICS
- Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20+ B-cell lymphoma
- (2015) Annegret Reichwagen et al. PHARMACOGENOMICS
- Genetic variants inSLC22A17 and SLC22A7are associated with anthracycline-induced cardiotoxicity in children
- (2015) Henk Visscher et al. PHARMACOGENOMICS
- Risk factors for anthracycline-associated cardiotoxicity
- (2015) Raquel E. Reinbolt et al. SUPPORTIVE CARE IN CANCER
- Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) M. Dreyling et al. ANNALS OF ONCOLOGY
- Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) D. A. Eichenauer et al. ANNALS OF ONCOLOGY
- First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials
- (2014) R.J. Young et al. EUROPEAN JOURNAL OF CANCER
- Hyaluronan Synthase 3 Variant and Anthracycline-Related Cardiomyopathy: A Report From the Children's Oncology Group
- (2014) Xuexia Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity
- (2013) Marzia Lotrionte et al. AMERICAN JOURNAL OF CARDIOLOGY
- Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC)
- (2013) C. Vulsteke et al. ANNALS OF ONCOLOGY
- Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia
- (2013) Steven E. Lipshultz et al. CANCER
- Validation of variants inSLC28A3andUGT1A6as genetic markers predictive of anthracycline-induced cardiotoxicity in children
- (2013) H. Visscher et al. PEDIATRIC BLOOD & CANCER
- Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity
- (2013) Brian C Jensen et al. PHARMACOGENOMICS
- Relationship Between theHLA-B*1502Allele and Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
- (2013) Wimonchat Tangamornsuksan et al. JAMA Dermatology
- A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor
- (2013) Joanna M. Lubieniecka et al. Frontiers in Genetics
- Single-Nucleotide Polymorphisms in Aldo-Keto and Carbonyl Reductase Genes Are Not Associated with Acute Cardiotoxicity after Daunorubicin Chemotherapy
- (2012) J. M. Lubieniecka et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- The relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 and glutathione S transferase Pi polymorphisms
- (2012) Bilge Volkan Salanci et al. JOURNAL OF CHEMOTHERAPY
- Unexpected doxorubicin-mediated cardiotoxicity in sisters: Possible role of polymorphisms in histamine n-methyl transferase
- (2012) Kamakshi Sachidanandam et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer
- (2011) K. Kitagawa et al. ANNALS OF ONCOLOGY
- Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma
- (2011) Rachael E. Windsor et al. CANCER
- ABCC1polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia
- (2011) Agnes F. Semsei et al. CELL BIOLOGY INTERNATIONAL
- Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children
- (2011) Henk Visscher et al. JOURNAL OF CLINICAL ONCOLOGY
- Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes—A Report From the Children's Oncology Group
- (2011) Javier G. Blanco et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional defect caused by the 4544G>A SNP in ABCC2
- (2011) Laure Elens et al. Pharmacogenetics and Genomics
- Variants at APOE influence risk of deep and lobar intracerebral hemorrhage
- (2010) Alessandro Biffi et al. ANNALS OF NEUROLOGY
- Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
- (2010) Lesley A Smith et al. BMC CANCER
- Strengthening the reporting of genetic association studies (STREGA)—an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement
- (2009) Julian Little et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21
- (2009) D Rossi et al. LEUKEMIA
- Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood
- (2009) Vladan Rajić et al. LEUKEMIA & LYMPHOMA
- ACE D/I polymorphism, migraine, and cardiovascular disease in women
- (2009) M. Schurks et al. NEUROLOGY
- Genetic polymorphisms in the carbonyl reductase 3 geneCBR3 and the NAD(P)H:quinone oxidoreductase 1 geneNQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer
- (2008) Javier G. Blanco et al. CANCER
- APOE genotype, ethnicity, and the risk of cerebral hemorrhage
- (2008) C. Tzourio et al. NEUROLOGY
- Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group
- (2008) S. M. Shankar et al. PEDIATRICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation